2025
Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, Dutta J, El-Fakhri G, McMeekin H, Pandit-Taskar N, Schwartz J, Shi K, Strigari L, Zaidi H, Saboury B, Rahmim A. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories. Journal Of Nuclear Medicine 2025, jnumed.124.267927. PMID: 39947910, DOI: 10.2967/jnumed.124.267927.Peer-Reviewed Original ResearchRadiopharmaceutical therapyImage-based dosimetryPrediction of doseInternal dosimetryPersonalized treatment plansMetastatic diseaseDosimetryNuclear oncologyClinical outcomesNuclear medicineClinical endpointsTreatment planningOncology communityDose responseEtiological mechanismsTargeted deliveryRadiobiologyRadiotherapyMalignancyRadiationLong-termTherapyPharmacotherapyDoseRadiopharmacokineticsComputational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins
Strigari L, Schwarz J, Bradshaw T, Brosch-Lenz J, Currie G, El-Fakhri G, Jha A, Mežinska S, Pandit-Taskar N, Roncali E, Shi K, Uribe C, Yusufaly T, Zaidi H, Rahmim A, Saboury B. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins. Journal Of Nuclear Medicine 2025, jnumed.124.268186. PMID: 39848769, DOI: 10.2967/jnumed.124.268186.Peer-Reviewed Original ResearchRadiopharmaceutical therapyNuclear oncologySociety of Nuclear MedicinePredictive dosimetryDosimetric informationTreatment planningTreatment outcomesLack of reimbursementTreatment personalizationDose responseTreatment optimizationEtiological mechanismsRobust security measuresPatient consentReal-world systemsNuclear medicineCross-border data sharingPatientsTreatmentEthical approval
2024
The time sensitive and dose-responsive association between parental corporal punishment and sleep disturbances in preschoolers: A prospective cohort study
Wang Z, Tang Y, Ordway M, Cui N, Rong T, Deng Y, Li W, Liu J, Zhao M, Jiang F, Wang G. The time sensitive and dose-responsive association between parental corporal punishment and sleep disturbances in preschoolers: A prospective cohort study. Child Abuse & Neglect 2024, 154: 106866. PMID: 38852431, DOI: 10.1016/j.chiabu.2024.106866.Peer-Reviewed Original ResearchDose-response associationAssociated with increased oddsRisk of sleep disturbancesProspective cohort studySleep disturbanceCohort studyExposure to corporal punishmentShanghai Children's HealthMaternal education levelOdds of sleep disturbancesAssociated with increased riskPositive parenting strategiesFamily annual incomeChildren's HealthLifestyle evaluationEducation levelConcurrent sleep disturbancesChildren's riskLogistic regressionWave 3Child ageWave 1Annual incomeDose responseParenting strategiesImpact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
Petrylak D, Chia Y, Yu E, Powles T, Flaig T, Loriot Y, O'Donnell P, Heath E, Kojima T, Park S, Sonpavde G, Picus J, Matsubara N, Obara W, Chudasama V, Poondru S, Harrison M, Kim E, Brancato S, Rosenberg J. Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer. Journal Of Clinical Oncology 2024, 42: 4503-4503. DOI: 10.1200/jco.2024.42.16_suppl.4503.Peer-Reviewed Original ResearchMetastatic urothelial cancerEnfortumab vedotinDose modificationEV exposureUrothelial cancerPre-dose samplesAssociated with lower riskPopulation PK modelLikelihood of responseEV-201Median PFSOS benefitOS outcomesDose reductionExposure quartilesExposure-responsePK assessmentEfficacy outcomesSafety profilePeripheral neuropathySkin reactionsPK modelLow riskSafety outcomesDose responseIndividualized Dose-Response to Statins Associated With Cardiovascular Disease Outcomes
Aggarwal S, Jiang L, Liu G, Grabowska M, Ong H, Wilke R, Feng Q, Wei W. Individualized Dose-Response to Statins Associated With Cardiovascular Disease Outcomes. JACC Advances 2024, 3: 100894. PMID: 38737008, PMCID: PMC11086740, DOI: 10.1016/j.jacadv.2024.100894.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseAtherosclerotic cardiovascular disease eventsLDL-CComposite primary end pointPrevention of atherosclerotic cardiovascular diseaseDose responseLow-density lipoprotein cholesterolBaseline LDL-CPrimary end pointAll-cause mortalityElectronic health record dataTime-to-event analysisHealth record dataCardiovascular disease outcomesIndividual dose responsesMultiple dosesClinical outcomesPrescribed statinsLipoprotein cholesterolHazard ratioStatinsEnd pointsDisease outcomeCardiovascular diseaseED50Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AML
Chen G, Abboud C, Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Leung E, Chen M, Natwa M, Spross J, Li K, Desai A, Wahl R, Brodin P, Pandit-Taskar N. Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AML. Transplantation And Cellular Therapy 2024, 30: s114-s115. DOI: 10.1016/j.jtct.2023.12.180.Peer-Reviewed Original ResearchPrimary endpointBone marrowLiver doseDose responseCurative allogeneic hematopoietic cell transplantationDose toleranceControlled phase 3 studiesEradication of leukemic cellsRate of hematologic toxicityAllogeneic hematopoietic cell transplantationConventional careTotal body irradiationPhase 3 studyHematopoietic cell transplantationRadiation dose toleranceDiseased bone marrowDoses to liverRadiation dose responseDose-response relationshipDose to target tissuesRadiation dose to liverAcute GVHDR/R AMLHematologic toxicityComplete remission
2023
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
Antozzi C, Guptill J, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Sevilla T, Jouvin M, Jin J, Karcher K, Ramchandren S, Sun H, Ling L, Zhu Y, Arroyo S, Group F. Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis. Neurology 2023, 102: e207937. PMID: 38165333, PMCID: PMC10962909, DOI: 10.1212/wnl.0000000000207937.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsGeneralized myasthenia gravisSignificant dose responseAdverse eventsMG-ADLDay 57Myasthenia gravisDose responseMyasthenia Gravis ActivitiesPrimary safety endpointPrimary efficacy endpointSerious adverse eventsPhase 2 studyReceptor monoclonal antibodyDaily living (IADL) total scoreClinical trial registrationMG-ADL scoreDose-dependent reductionEudraCT numberQ2W groupEfficacy endpointPlacebo groupSafety endpointCare therapyReceptor autoantibodies
2022
Mechanistic considerations in 1,4-dioxane cancer risk assessment
Ginsberg G, Chen Y, Vasiliou V. Mechanistic considerations in 1,4-dioxane cancer risk assessment. Current Opinion In Environmental Science & Health 2022, 30: 100407. PMID: 37091947, PMCID: PMC10120849, DOI: 10.1016/j.coesh.2022.100407.Peer-Reviewed Original ResearchCarcinogenic effectsLinear low-dose extrapolationGenders of ratsDose responseInduction of CYP2E1Human liver cancerCancer risk assessmentLow-dose extrapolationLiver cancerLow doseAnimal studiesDose levelsChronic exposureLow human exposureDose extrapolationCarcinogenic responseStandard test batteryVivo genotoxicityRisk assessmentOxidative stressDisease-related processesOwn metabolismLess likelihoodMode of actionHuman exposure
2021
Progesterone Modulates Mitochondrial Functions in Human Glioblastoma Cells
Atif F, Yousuf S, Espinosa-Garcia C, Stein D. Progesterone Modulates Mitochondrial Functions in Human Glioblastoma Cells. Molecular Neurobiology 2021, 58: 3805-3816. PMID: 33847913, DOI: 10.1007/s12035-021-02382-1.Peer-Reviewed Original ResearchConceptsExtracellular acidification rateEffects of P4Glioblastoma multiformeGlioblastoma multiforme cell linesGlioblastoma multiforme cellsCell linesInhibitory effectDecreased tumor sizeSuperoxide radical generationMitochondrial functionDose-dependent inhibitory effectOxygen consumption rateTime-response studiesMitochondrial respirationHuman glioblastoma multiformeMitochondrial stress testSpread of glioblastoma multiformeCompared to controlsTumor sizeConcentrations of P4Human glioblastoma cellsModulate mitochondrial functionNonmitochondrial oxygen consumptionMaximum inhibitory effectDose response
2020
Muscarinic M1 Receptors Modulate Working Memory Performance and Activity via KCNQ Potassium Channels in the Primate Prefrontal Cortex
Galvin VC, Yang ST, Paspalas CD, Yang Y, Jin LE, Datta D, Morozov YM, Lightbourne TC, Lowet AS, Rakic P, Arnsten AFT, Wang M. Muscarinic M1 Receptors Modulate Working Memory Performance and Activity via KCNQ Potassium Channels in the Primate Prefrontal Cortex. Neuron 2020, 106: 649-661.e4. PMID: 32197063, PMCID: PMC7244366, DOI: 10.1016/j.neuron.2020.02.030.Peer-Reviewed Original ResearchConceptsKCNQ channelsInverted-U dose responseCell firingPrefrontal cortexMuscarinic M1 receptorsKCNQ potassium channelsSingle-unit recordingsPrimate prefrontal cortexDorsolateral prefrontal cortexCholinergic alterationsKCNQ isoformsM1 receptorsPyramidal neuronsCholinergic depletionMuscarinic M1Cognitive disordersAged monkeysPersistent firingRecurrent excitationPotassium channelsAppropriate targetsDose responseM1R stimulationSensory inputCortex
2018
Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery
Kumar N, Lochhead J, Pizzo M, Nehra G, Boroumand S, Greene G, Thorne R. Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery. Journal Of Controlled Release 2018, 286: 467-484. PMID: 30081144, PMCID: PMC7234798, DOI: 10.1016/j.jconrel.2018.08.006.Peer-Reviewed Original ResearchConceptsTrigeminal nerveIntranasal administrationDose responseBlood-cerebrospinal fluid barrierPerivascular spacesAdult female ratsBlood vesselsRat nervous systemMatrix metalloproteinase-9Immunoglobulin G antibodiesIntranasal doseIntranasal deliveryNasal epitheliaFemale ratsOlfactory bulbCerebral blood vesselsNasal mucosaPermeation enhancersBrain concentrationsTherapeutic levelsTracer doseMetalloproteinase-9Cranial nervesHigh dosesIntranasal routeNonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals
Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgün KM, Gibert CL, Re V, Rimland D, Womack JA, Wyatt CM, Tate JP, Team V. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS 2018, 32: 739-749. PMID: 29543653, PMCID: PMC5868488, DOI: 10.1097/qad.0000000000001756.Peer-Reviewed Original ResearchConceptsAdverse health outcomesHIV statusUninfected individualsVACS IndexMedication countUS Veterans Affairs Healthcare SystemHealth outcomesVeterans Affairs Healthcare SystemRisk of hospitalizationSeverity of illnessHIV-1 RNAHIV-positive individualsRisk of mortalityDose responseRace/ethnicityPolypharmacyFiscal year 2009HospitalizationMedicationsMortalityHealthcare systemAntiretroviralsOutcomesAssociationRisk
2017
ROC-king onwards: intraepithelial lymphocyte counts, distribution & role in coeliac disease mucosal interpretation
Rostami K, Marsh M, Johnson M, Mohaghegh H, Heal C, Holmes G, Ensari A, Aldulaimi D, Bancel B, Bassotti G, Bateman A, Becheanu G, Bozzola A, Carroccio A, Catassi C, Ciacci C, Ciobanu A, Danciu M, Derakhshan M, Elli L, Ferrero S, Fiorentino M, Fiorino M, Ganji A, Ghaffarzadehgan K, Going J, Ishaq S, Mandolesi A, Mathews S, Maxim R, Mulder C, Neefjes-Borst A, Robert M, Russo I, Rostami-Nejad M, Sidoni A, Sotoudeh M, Villanacci V, Volta U, Zali M, Srivastava A. ROC-king onwards: intraepithelial lymphocyte counts, distribution & role in coeliac disease mucosal interpretation. Gut 2017, 66: 2080. PMID: 28893865, PMCID: PMC5749338, DOI: 10.1136/gutjnl-2017-314297.Peer-Reviewed Original ResearchConceptsIntraepithelial lymphocyte countsReceiver operating characteristicIntraepithelial lymphocytesCoeliac diseaseMarsh III lesionsIII lesionsHistological diagnosis of coeliac diseaseNormal controlsReceiver operating characteristic curve analysisDiagnosis of coeliac diseaseOptimal cut-off pointReceiver operating characteristic analysisOptimal cut-offCount intraepithelial lymphocytesCut-off pointCut-offHistological diagnosisLymphocyte countMulticentre studyDuodenal biopsiesAntigenic influenceCurve analysisBiopsyDose responseControl groupAssessment of Protein Turnover in Health and Disease
Wernerman J, Morris C, Paddon‐Jones D, Sarav M. Assessment of Protein Turnover in Health and Disease. Nutrition In Clinical Practice 2017, 32: 15s-20s. PMID: 28388375, DOI: 10.1177/0884533617694611.Peer-Reviewed Original Research
2014
Impact of Cannabis Use on the Development of Psychotic Disorders
Wilkinson ST, Radhakrishnan R, D’Souza D. Impact of Cannabis Use on the Development of Psychotic Disorders. Current Addiction Reports 2014, 1: 115-128. PMID: 25767748, PMCID: PMC4352721, DOI: 10.1007/s40429-014-0018-7.BooksAcute psychosisPsychotic disordersCannabis useAcute intoxicationPersistent psychotic disordersLater psychotic disorderPersistence of psychosisPersistent psychosisHealthy volunteersCognitive symptomsCannabis intoxicationCannabinoid usePsychosisVulnerable populationsComponent causesCannabisIntoxicationGenetic vulnerabilityDose responseSynthetic cannabinoidsChildhood abuseDisordersCannabinoidsPotential riskMore research
2013
Characterization of Statin Dose Response in Electronic Medical Records
Wei W, Feng Q, Jiang L, Waitara M, Iwuchukwu O, Roden D, Jiang M, Xu H, Krauss R, Rotter J, Nickerson D, Davis R, Berg R, Peissig P, McCarty C, Wilke R, Denny J. Characterization of Statin Dose Response in Electronic Medical Records. Clinical Pharmacology & Therapeutics 2013, 95: 331-338. PMID: 24096969, PMCID: PMC3944214, DOI: 10.1038/clpt.2013.202.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAllelesAtorvastatinCholesterol, LDLCohort StudiesDatabases, FactualDose-Response Relationship, DrugElectronic Health RecordsGenotypeHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasLipid MetabolismLipidsPhenotypePolymorphism, Single NucleotidePyrrolesRandomized Controlled Trials as TopicSimvastatin
2012
Cadmium Risk Assessment in Relation to Background Risk of Chronic Kidney Disease
Ginsberg GL. Cadmium Risk Assessment in Relation to Background Risk of Chronic Kidney Disease. Journal Of Toxicology And Environmental Health Part A 2012, 75: 374-390. PMID: 22524593, DOI: 10.1080/15287394.2012.670895.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseKidney diseaseU.S. Environmental Protection Agency reference dosesStage 3 chronic kidney diseaseNoncancer effectsPopulation riskCurrent dietary exposureMinimum risk levelLower Cd doseCKD riskDisease Registry's Minimum Risk LevelDaily doseLow doseChronic daily doseSwedish womenDietary exposureLeft shiftAdverse effectsCd doseDiseaseCadmium risk assessmentDoseReference dosesDose responseGFR
2009
Improved MAGIC gel for higher sensitivity and elemental tissue equivalent 3D dosimetry
Zhu X, Reese T, Crowley E, Fakhri G. Improved MAGIC gel for higher sensitivity and elemental tissue equivalent 3D dosimetry. Medical Physics 2009, 37: 183-188. PMID: 20175480, PMCID: PMC2801736, DOI: 10.1118/1.3260844.Peer-Reviewed Original ResearchConceptsMAGIC gelTissue equivalentsGel dosimeterRange verificationNuclear reactionsDosimetry applicationsProton beam therapyPhantom materialTime-activity measurementsDosimetry purposesTransverse relaxation rateRelaxation rateBeam therapyDose-response curveSlopes of dose-response curvesGel formulationMAGICDose responseMelting pointSoft tissueDosimetersPhantomTime-activityProtonGlucosePrenatal Exposure to Acetaminophen and Asthma in Children
Kang EM, Lundsberg LS, Illuzzi JL, Bracken MB. Prenatal Exposure to Acetaminophen and Asthma in Children. Obstetrics And Gynecology 2009, 114: 1295-1306. PMID: 19935033, PMCID: PMC3237391, DOI: 10.1097/aog.0b013e3181c225c0.Peer-Reviewed Original ResearchConceptsRisk of asthmaAdjusted odds ratioThird trimesterPrenatal exposureMonths of deliveryWeeks of gestationUse of acetaminophenYears of lifeLogistic regression modelsAcetaminophen useAsthma symptomsPregnant womenPotential confoundersOdds ratioAsthmaPregnancyAcetaminophenDose responseTrimesterChildrenRiskMonthsWomenRegression modelsExposure
2007
On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned 131Cs Prostate Brachytherapy
Chen ZJ, Deng J, Roberts K, Nath R. On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned 131Cs Prostate Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2007, 70: 303-310. PMID: 17980500, PMCID: PMC2289996, DOI: 10.1016/j.ijrobp.2007.09.007.Peer-Reviewed Original ResearchConceptsDose reductionProstate brachytherapyDose compensationLarge edemaBiochemical recurrence-free survivalRecurrence-free survivalSignificant dose reductionEffects of edemaSublethal damage repairAdditional irradiationPrescription doseProstate cancerIndividual patientsEdemaEdema evolutionPrescribed doseProstate edemaEffective doseRadiobiologic effectsBrachytherapyDoseProstate implantsDose responseImplants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply